IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
IQVIA Greater China R&D
After 21 years of expansion in Greater China (first office opened in 1997), we now have more 2,200 employees in Greater China. We have developed an integrated drug development offering to help companies of all sizes and types grow and succeed. Our infrastructure and capabilities in Greater China include: offices in Beijing, Shanghai, Dalian, Hong Kong and Taipei, allowing it to serve all major population centers and study sites; a world-class Central Lab in Beijing, with biomarker and pathology capabilities; and customized local solutions through our local subsidiary, Kun Tuo.
- Provide clinical proposal
- Clinical operation
- Data management and statistics
- Project management
- Medical affairs